Email updates

Keep up to date with the latest news and content from JN and BioMed Central.

Open Access Research

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7

Christopher B Fox1, Sandra J Sivananthan1, Malcolm S Duthie1, Julie Vergara1, Jeffrey A Guderian1, Elliot Moon2, David Coblentz2, Steven G Reed1 and Darrick Carter13*

Author Affiliations

1 Infectious Disease Research Institute (IDRI), Seattle, WA, USA

2 DFNet Research, Seattle, WA, USA

3 PAI Life Sciences, 1616 Eastlake Ave E Suite 500, Seattle 98102 WA, USA

For all author emails, please log on.

Journal of Nanobiotechnology 2014, 12:17  doi:10.1186/1477-3155-12-17

Published: 26 April 2014

Abstract

Background

Recent reports that TLR4 and TLR7 ligands can synergistically trigger Th1 biased immune responses suggest that an adjuvant that contains both ligands would be an excellent candidate for co-administration with vaccine antigens for which heavily Th1 biased responses are desired. Ligands of each of these TLRs generally have disparate biochemical properties, however, and straightforward co-formulation may represent an obstacle.

Results

We show here that the TLR7 ligand, imiquimod, and the TLR4 ligand, GLA, synergistically trigger responses in human whole blood. We combined these ligands in an anionic liposomal formulation where the TLR7 ligand is in the interior of the liposome and the TLR4 ligand intercalates into the lipid bilayer. The new liposomal formulations are stable for at least a year and have an attractive average particle size of around 140 nm allowing sterile filtration. The synergistic adjuvant biases away from Th2 responses, as seen by significantly reduced IL-5 and enhanced interferon gamma production upon antigen-specific stimulation of cells from immunized mice, than any of the liposomal formulations with only one TLR agonist. Qualitative alterations in antibody responses in mice demonstrate that the adjuvant enhances Th1 adaptive immune responses above any adjuvant containing only a single TLR ligand as well.

Conclusion

We now have a manufacturable, synergistic TLR4/TLR7 adjuvant that is made with excipients and agonists that are pharmaceutically acceptable and will have a straightforward path into human clinical trials.

Keywords:
TLR4; TLR7; Synergy; Adjuvant; Manufacturability; Liposome